看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。* M G/ @) V( Z( A" c7 O$ {' \
7 R6 C7 R! L" g* O5 {
" Y) X. V( [3 v, \
Currently available feasibility data for possible combination strategies. ; X0 U, Q% s* O+ ~, ?5 h
————————————————————————————————0 C. e2 {4 h# S
Combination Feasibility according to preliminary data 0 G7 Z9 W+ q5 ~3 f4 v% n
——————————————————————————————————- R. d8 g2 Z* i1 X0 [: _
Bevacizumab + sorafenib Yes, reduced dose
# Q* P) }' k7 l& xBevacizumab + sunitinib† No : @5 j* ^' t( ~0 [
Bevacizumab + temsirolimus Yes / d+ a" K& H4 Y, M5 b8 C; B$ T
Bevacizumab + everolimus Yes 2 b3 o, g8 L9 ?% k; E' w M
Sorafenib + sunitinib ?
0 C3 o: @+ B& q* A/ uSorafenib + temsirolimus Yes, reduced dose & P" W8 l3 Y- n1 |+ [
Sorafenib + everolimus Yes, reduced dose
, {2 c% w+ m/ m, l* }- M0 q6 }Sunitinib + temsirolimus† No
4 B7 F, M. m! _, r3 KSunitinib + everolimus ?
; w1 X9 ^, ]; m- r! x9 QTemsirolimus + everolimus ? 2 n" e9 H- A7 d+ @$ ]3 e" Y
————————————————————
0 g3 D: u) V' U. M. h2 c* a( C: B†Led to US FDA warning.3 U$ F; M e/ W3 P8 P
?: As yet unattempted combination.
* Q! l0 O9 Y! |; E3 v: X |